Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ATOS's Cash to Debt is ranked higher than
88% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ATOS: No Debt )
ATOS' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ATOS's Equity to Asset is ranked higher than
97% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ATOS: 0.91 )
ATOS' s 10-Year Equity to Asset Range
Min: -0.66   Max: 0.95
Current: 0.91

-0.66
0.95
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
87% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. ATOS: No Debt )
ATOS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 13.03
M-Score: -5.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -13810.71
ATOS's Operating margin (%) is ranked lower than
54% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. ATOS: -13810.71 )
ATOS' s 10-Year Operating margin (%) Range
Min: -171450   Max: -1051.66
Current: -13810.71

-171450
-1051.66
Net-margin (%) -13813.10
ATOS's Net-margin (%) is ranked lower than
54% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. ATOS: -13813.10 )
ATOS' s 10-Year Net-margin (%) Range
Min: -172100   Max: -1053.94
Current: -13813.1

-172100
-1053.94
ROE (%) -75.41
ATOS's ROE (%) is ranked higher than
55% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. ATOS: -75.41 )
ATOS' s 10-Year ROE (%) Range
Min: -972.32   Max: -136.71
Current: -75.41

-972.32
-136.71
ROA (%) -68.69
ATOS's ROA (%) is ranked higher than
54% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. ATOS: -68.69 )
ATOS' s 10-Year ROA (%) Range
Min: -223   Max: -102.65
Current: -68.69

-223
-102.65
ROC (Joel Greenblatt) (%) -5390.80
ATOS's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ATOS: -5390.80 )
ATOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6678.02   Max: -1143
Current: -5390.8

-6678.02
-1143
» ATOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
ATOS's P/B is ranked higher than
81% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. ATOS: 3.00 )
ATOS' s 10-Year P/B Range
Min: 1.03   Max: 22.55
Current: 3

1.03
22.55
P/S 475.40
ATOS's P/S is ranked lower than
52% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. ATOS: 475.40 )
ATOS' s 10-Year P/S Range
Min: 0   Max: 475.4
Current: 475.4

0
475.4
EV-to-EBIT -2.79
ATOS's EV-to-EBIT is ranked higher than
57% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ATOS: -2.79 )
ATOS' s 10-Year EV-to-EBIT Range
Min: -24.7   Max: -0.5
Current: -2.79

-24.7
-0.5
Current Ratio 7.61
ATOS's Current Ratio is ranked higher than
94% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ATOS: 7.61 )
ATOS' s 10-Year Current Ratio Range
Min: 0.01   Max: 16.36
Current: 7.61

0.01
16.36
Quick Ratio 7.58
ATOS's Quick Ratio is ranked higher than
95% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ATOS: 7.58 )
ATOS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 16.36
Current: 7.58

0.01
16.36
Days Inventory 16.93
ATOS's Days Inventory is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. ATOS: 16.93 )
ATOS' s 10-Year Days Inventory Range
Min: 0   Max: 0
Current: 16.93

Days Sales Outstanding 126.01
ATOS's Days Sales Outstanding is ranked higher than
62% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. ATOS: 126.01 )
ATOS' s 10-Year Days Sales Outstanding Range
Min: 80.15   Max: 182.5
Current: 126.01

80.15
182.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.50
ATOS's Price/Net Cash is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ATOS: 4.50 )
ATOS' s 10-Year Price/Net Cash Range
Min: 2.68   Max: 390
Current: 4.5

2.68
390
Price/Net Current Asset Value 4.50
ATOS's Price/Net Current Asset Value is ranked higher than
94% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ATOS: 4.50 )
ATOS' s 10-Year Price/Net Current Asset Value Range
Min: 2.49   Max: 130
Current: 4.5

2.49
130
Price/Tangible Book 4.10
ATOS's Price/Tangible Book is ranked higher than
81% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. ATOS: 4.10 )
ATOS' s 10-Year Price/Tangible Book Range
Min: 2.45   Max: 97.5
Current: 4.1

2.45
97.5
Earnings Yield (Greenblatt) -35.50
ATOS's Earnings Yield (Greenblatt) is ranked lower than
52% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ATOS: -35.50 )
ATOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -60.8   Max: 0
Current: -35.5

-60.8
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:YAG.Germany,
Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics (ATOS) Soars on Distribution Deal, Conn's (CONN) Rating Boosted Feb 09 2015 
Atossa Genetics Announces the Publication of: Proliferative Epithelial Disease Identified in Nipple Jan 19 2015 
Atossa Genetics to Present at Upcoming Investor Conferences in January 2015 Jan 06 2015 
Atossa Genetics Inc. Provides Update on Pharmacogenetics Testing Now Offered by The National Referen Dec 19 2014 
Atossa Genetics Inc. Hires Pieter van der Poel as Vice President of European Commercial Operations Dec 16 2014 
Atossa Genetics Inc. Announces Successful Closure of FDA Inspections Dec 05 2014 
Atossa Genetics Inc. Announces Contract With Rhenus Advanced Services B.V. Dec 02 2014 
Atossa Genetics to Announce Third Quarter 2014 Financial Results and Provide a Company Update on Wed Nov 07 2014 
Atossa Genetics Inc. Wins Dismissal of Securities Class Action Litigation Oct 31 2014 
Atossa Genetics Receives CE Mark for the ForeCYTE Breast Aspirator Device Oct 22 2014 

More From Other Websites
ATOS: Atossa Reports Better than Expected Financial Results for 2014 Mar 31 2015
ATOSSA GENETICS INC Files SEC form 10-K, Annual Report Mar 30 2015
ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 30 2015
Atossa Genetics Announces 2014 Financial Results and Provides Company Update Mar 30 2015
Atossa Genetics to Host 2014 Financial Results and Company Update Conference Call on Monday, March... Mar 26 2015
ATOS: Atossa Launches the FullCYTE Breast Aspirator in the US Mar 24 2015
Atossa Genetics Launches the FullCYTE Breast Aspirator in the United States Mar 24 2015
Atossa Genetics Launches the ForeCYTE Breast Aspirator Within the European Union Mar 04 2015
ATOS: Two Deals: Key Steps toward the Official Launch of FullCYTE Breast Aspirator Mar 02 2015
Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health... Feb 27 2015
Henry Schein Medical to Offer Atossa Genetics' FullCYTE Breast Aspirator Feb 26 2015
Atossa Genetics to Exhibit at Two Medical Conferences: 8th Annual International Symposium on the... Feb 17 2015
Atossa Genetics Signs National Distribution Agreement With Thermo Fisher Scientific for FullCYTE... Feb 09 2015
5 things to know: Including DFW ranks highly for Hispanics and the economy Feb 03 2015
Atossa Genetics Announces the Publication of: Proliferative Epithelial Disease Identified in Nipple... Jan 19 2015
ATOSSA GENETICS INC Files SEC form 8-K, Regulation FD Disclosure Jan 15 2015
ORYZON Appoints Greg Weaver as Global Chief Financial Officer Jan 12 2015
Atossa Genetics to Present at Upcoming Investor Conferences in January 2015 Jan 06 2015
Atossa Genetics (ATOS) Stock Declines Today on Heavy Trading Volume Dec 29 2014
ATOS: A Pure Play Breast Care Company with Great Potential to Grow Dec 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK